Togo Y, McCracken E A
J Infect Dis. 1976 Jun;133 Suppl:A109-13. doi: 10.1093/infdis/133.supplement_2.a109.
The prophylactic effectiveness of oral administration of ribavirin (1-beta-D-ribofuranosyl-1,24-triazole-3-carboxamide, virazole) against artificially induced influenza B infection was evaluated in a double-blind clinical trial. Fifteen seronegative men received ribavirin capsules (600 mg/day in three divided doses), and 15 other men received placebo capsules two days before the inoculation of 6.4 X 10(4) 50% tissue culture infective doses of influenza virus B/Georgia/26/74 and for eight days after challenge. Ten men (69%) in each of the two groups developed mild to severe influenzal illness. Of these, five placebo-treated men developed severe febrile illness, while only one drug-treated man had illness of comparable severity. Illness of moderate severity was observed in three placebo-treated conrols and two drug recipients. There was no difference between the frequencies of isolation of virus or the anitbody responses in the two groups. Ribavirin suppressed signs and symptoms induced by influenza B challenge, but its effectiveness was marginal.
在一项双盲临床试验中，评估了口服利巴韦林（1-β-D-呋喃核糖基-1,2,4-三唑-3-羧酰胺，病毒唑）对人工诱发的乙型流感感染的预防效果。15名血清阴性男性在接种6.4×10⁴ 50%组织培养感染剂量的乙型流感病毒B/佐治亚/26/74前两天接受利巴韦林胶囊（600毫克/天，分三次服用），另外15名男性接受安慰剂胶囊，并在激发后持续八天。两组中各有10名男性（69%）出现了轻度至重度流感样疾病。其中，5名接受安慰剂治疗的男性出现了严重发热疾病，而接受药物治疗的男性中只有1人出现了同等严重程度的疾病。在3名接受安慰剂治疗的对照组和2名接受药物治疗的受试者中观察到了中度严重程度的疾病。两组在病毒分离频率或抗体反应方面没有差异。利巴韦林抑制了乙型流感激发引起的体征和症状，但其效果有限。
